Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

228 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nephrotoxicity of Vancomycin in Combination With Beta-Lactam Agents: Ceftolozane-Tazobactam vs Piperacillin-Tazobactam.
Alosaimy S, Lagnf AM, Hobbs ALV, Mubarez M, Kufel WD, Morrisette T, Polisetty RS, Li D, Veve MP, Simon SP, Truong J, Finch N, Venugopalan V, Rico M, Amaya L, Yost C, Cubillos A, Chandler E, Patch M, Smith IMK, Biagi M, Wrin J, Moore WJ, Molina KC, Rebold N, Holger D, Kunz Coyne AJ, Jorgensen SCJ, Witucki P, Tran NN, Davis SL, Sakoulas G, Rybak MJ. Alosaimy S, et al. Among authors: venugopalan v. Clin Infect Dis. 2023 Feb 8;76(3):e1444-e1455. doi: 10.1093/cid/ciac670. Clin Infect Dis. 2023. PMID: 35982631
Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections.
Alosaimy S, Jorgensen SCJ, Lagnf AM, Melvin S, Mynatt RP, Carlson TJ, Garey KW, Allen D, Venugopalan V, Veve M, Athans V, Saw S, Yost CN, Davis SL, Rybak MJ. Alosaimy S, et al. Among authors: venugopalan v. Open Forum Infect Dis. 2020 Feb 19;7(3):ofaa051. doi: 10.1093/ofid/ofaa051. eCollection 2020 Mar. Open Forum Infect Dis. 2020. PMID: 32161775 Free PMC article.
Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa.
Alosaimy S, Lagnf AM, Morrisette T, Scipione MR, Zhao JJ, Jorgensen SCJ, Mynatt R, Carlson TJ, Jo J, Garey KW, Allen D, DeRonde K, Vega AD, Abbo LM, Venugopalan V, Athans V, Saw S, Claeys KC, Miller M, Molina KC, Veve M, Kufel WD, Amaya L, Yost C, Ortwine J, Davis SL, Rybak MJ. Alosaimy S, et al. Among authors: venugopalan v. Open Forum Infect Dis. 2021 Jul 14;8(8):ofab371. doi: 10.1093/ofid/ofab371. eCollection 2021 Aug. Open Forum Infect Dis. 2021. PMID: 34430671 Free PMC article.
Effectiveness and Safety of Beta-Lactam Antibiotics with and without Therapeutic Drug Monitoring in Patients with Pseudomonas aeruginosa Pneumonia or Bloodstream Infection.
Kunz Coyne AJ, Alshaer M, Casapao AM, Venugopalan V, Isache C, Ferreira J, Jankowski CA. Kunz Coyne AJ, et al. Among authors: venugopalan v. Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0064622. doi: 10.1128/aac.00646-22. Epub 2022 Sep 8. Antimicrob Agents Chemother. 2022. PMID: 36073943 Free PMC article.
Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase-producing Enterobacterales bloodstream infections (REDUCE-BSI).
Vu CH, Venugopalan V, Santevecchi BA, Voils SA, Ramphal R, Cherabuddi K, DeSear K. Vu CH, et al. Among authors: venugopalan v. Antimicrob Steward Healthc Epidemiol. 2022 Mar 11;2(1):e39. doi: 10.1017/ash.2022.21. eCollection 2022. Antimicrob Steward Healthc Epidemiol. 2022. PMID: 36310806 Free PMC article.
Re-evaluation of cefepime or piperacillin/tazobactam to decrease use of carbapenems in ESBL-producing Enterobacterales urinary tract infections (REDUCE-UTI).
Branton AC, Vu CH, Venugopalan V, Santevecchi BA, Cherabuddi K, Ramphal R, Manohar T, Desear KE. Branton AC, et al. Among authors: venugopalan v. JAC Antimicrob Resist. 2023 Mar 17;5(2):dlad021. doi: 10.1093/jacamr/dlad021. eCollection 2023 Apr. JAC Antimicrob Resist. 2023. PMID: 36936190 Free PMC article.
Use of therapeutic drug monitoring to characterize cefepime-related neurotoxicity.
Venugopalan V, Casaus D, Kainz L, Slaton CN, Hurst N, Bruzzone M, Hu C, Sword G, Cherabuddi K, Iovine N, Liu J, Scheetz MH, Rhodes N, Maranchick N, Peloquin CA, Klinker K, Alshaer MH. Venugopalan V, et al. Pharmacotherapy. 2023 Jan;43(1):6-14. doi: 10.1002/phar.2744. Epub 2022 Dec 2. Pharmacotherapy. 2023. PMID: 36401796
228 results